A NEW GENERATION OF ANGIOTENSIN II RECEPTOR BLOCKERS AS PATHOGENETIC CORRECTION OF THE METABOLIC SYNDROME

2018 ◽  
Vol 25 (3) ◽  
pp. 218-219
Author(s):  
Vitalina Petrenko ◽  
Anatoliy Kubyshkin ◽  
Irina Fomochkina ◽  
Natalia Kornienko ◽  
Alexander Kucherenko
Keyword(s):  
Metabolic Syndrome ◽  
Angiotensin Ii ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
The Metabolic Syndrome ◽  
Receptor Blockers ◽  
New Generation

A NEW GENERATION OF ANGIOTENSIN II RECEPTOR BLOCKERS AS PATHOGENETIC CORRECTION OF THE METABOLIC SYNDROME

2018 ◽  
Vol 25 (3) ◽  
pp. 213
Author(s):  
Vitalina Petrenko ◽  
Anatoliy Kubyshkin ◽  
Irina Fomochkina ◽  
Natalia Kornienko ◽  
Alexander Kucherenko
Keyword(s):  
Metabolic Syndrome ◽  
Angiotensin Ii ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
The Metabolic Syndrome ◽  
Receptor Blockers ◽  
New Generation

scholarly journals Efficacy of irbesartan in arterial hypertension and metabolic syndrome

2013 ◽  
Vol 10 (2) ◽  
pp. 53-56
Author(s):  
O D Ostroumova ◽  
A A Zykova ◽  
T A Polosova ◽  
O V Bondarets
Keyword(s):  
Metabolic Syndrome ◽  
Angiotensin Ii ◽  
Arterial Hypertension ◽  
Antihypertensive Drugs ◽  
Angiotensin Ii Receptor Blockers ◽  
Efficacy And Safety ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Patients ◽  
Receptor Blockers

The paper gives the data of Russian guidelines for the diagnosis and approaches to treating metabolic syndrome. It considers the choice of antihypertensive drugs in the treatment of hypertensive patients with metabolic syndrome. The benefits of angiotensin II receptor blockers are shown. The results of a number of trials evaluating the efficacy and safety of irbesartan used to manage arterial hypertension in metabolic syndrome are analyzed.

The Impact of Angiotensin-II Receptor Blockers on Cardiovascular Events in Hypertensive Patients – Evidence from Real-life Databases

2010 ◽  
Vol 6 (3) ◽  
pp. 33
Author(s):  
Robert J Petrella ◽  
Keyword(s):  
Angiotensin Ii ◽  
Antihypertensive Drugs ◽  
Real Life ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Real World Setting ◽  
Actual Experience ◽  
Receptor Blockers ◽  
Randomised Controlled ◽  
The Impact

It is widely recognised that hypertension is a major risk factor for the development of future cardiovascular (CV) events, which in turn are a major cause of morbidity and mortality. Blood pressure (BP) control with antihypertensive drugs has been shown to reduce the risk of CV events. Angiotensin-II receptor blockers (ARBs) are one such class of antihypertensive drugs and randomised controlled trials (RCTs) have shown ARB-based therapies to have effective BP-lowering properties. However, data obtained under these tightly controlled settings do not necessarily reflect actual experience in clinical practice. Real-life databases may offer alternative information that reflects an uncontrolled real-world setting and complements and expands on the findings of clinical trials. Recent analyses of practice-based real-life databases have shown ARB-based therapies to be associated with better persistence and adherence rates and with superior BP control than non-ARB-based therapies. Analyses of real-life databases also suggest that ARB-based therapies may be associated with a lower risk of CV events than other antihypertensive-drug-based therapies.

Sign in / Sign up

Export Citation Format

Share Document